04:26 PM EDT, 04/03/2025 (MT Newswires) -- NetraMark Holdings ( AINMF ) , at the close of trade Thursday said it reached a global agreement with Worldwide Clinical Trials, a full-service, global contract research organization.

The artificial intelligence company with involvement in pharmaceutical industry clinical trials said under the agreement, NetraMark's ( AINMF ) AI technology will initially be used for Phase 2 neuroscience and oncology clinical trials and select Phase 3 clinical trials conducted by Worldwide. However, broader availability will be made to all Worldwide sponsors across all therapeutic areas and trial phases.

As part of the collaboration, and to streamline workflow for sponsors, NetraMark's ( AINMF ) NetraAI platform will be incorporated into Worldwide's offerings.

NetraMark ( AINMF ) closed up $0.14, or 11%, on the Canadian Securities Exchange.